Fulcrum Therapeutics (Fulcrum Therapeutics) Accumulated other comprehensive income (loss) : $-0.14 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Fulcrum Therapeutics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Fulcrum Therapeutics's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $-0.14 Mil.

Fulcrum Therapeutics's quarterly Accumulated other comprehensive income (loss) increased from Jun. 2023 ($-1.20 Mil) to Sep. 2023 ($-0.89 Mil) and increased from Sep. 2023 ($-0.89 Mil) to Dec. 2023 ($-0.14 Mil).

Fulcrum Therapeutics's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 ($-0.40 Mil) to Dec. 2022 ($-0.80 Mil) but then increased from Dec. 2022 ($-0.80 Mil) to Dec. 2023 ($-0.14 Mil).

Fulcrum Therapeutics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Fulcrum Therapeutics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulcrum Therapeutics Accumulated other comprehensive income (loss) Chart

Fulcrum Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

-0.40

-0.80

-0.14

Fulcrum Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-0.80	-0.65	-1.20	-0.89	-0.14

Fulcrum Therapeutics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Fulcrum Therapeutics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Fulcrum Therapeutics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulcrum Therapeutics (Fulcrum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fulcrum Therapeutics Inc (NAS:FULC) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Landsdowne Street, Cambridge, MA, USA, 02139

Website

https://www.fulcrumtx.com

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Executives

Alan A Musso	officer: Chief Financial Officer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alex Sapir	director, officer: See Remarks	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Greg Tourangeau	officer: Controller	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J Gould	director, officer: President & CEO	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Santiago Arroyo	officer: Chief Medical Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Hayes Melvin H. Iii	officer: Chief Operating Officer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Esther Rajavelu	officer: Chief Financial Officer	26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sonja Banks	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bryan Stuart	officer: Chief Operating Officer	C/O CIVITAS THERAPEUTICS, INC., 190 EVERETT AVENUE, CHELSEA MA 02150
Christopher Moxham	officer: Chief Scientific Officer	26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Peter G. Thomson	officer: VP Finance & Accounting	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139